Pharmacodynamic interaction between midazolam and a specific benzodiazepine antagonist in humans.
The pharmacodynamic interaction between midazolam and the specific benzodiazepine antagonist Ro 15-1788 has been investigated in six healthy male volunteers. Hypnotic steady-state concentrations of midazolam (55 +/- 11 ng/mL; mean +/- SD) have been achieved rapidly by an intravenous bolus of 0.07 mg/kg and maintained by an individual but constant infusion rate of 0.025 to 0.04 mg/kg/hr for eight hours. Following a two-hour control period, the antagonist (2.5 mg) or the solvent were injected double-blind in random order. Three hours later, the other medication was administered. Whereas plasma levels of midazolam remained constant throughout the complete eight-hour trial (Clearance = 670 +/- 96 mL/min) concentrations of Ro 15-1788 declined rapidly with an elimination half-life between 0.7 and 1.8 hours and a total plasma clearance of 702 +/- 235 mL/min. Concentrations of Ro 15-1788 approached the analytic limit of 2 ng/mL within three hours. The pharmacodynamic response to midazolam and the antagonist was assessed by a sedation index using visual analogue scales, reaction time (RT) measurements, and transformed Fourier analysis of the power spectrum of the recorded electroencephalogram (EEG). About 30 to 45 seconds following the injection of Ro 15-1788, hypnotic action of midazolam was completely reversed as visualized by return to alpha rhythm in the EEG, shortening of prolonged RT, and normalization of the elevated sedation index. The antagonistic action lasted for about two to three hours. The abrupt arousal from sleep was not associated with any unpleasant sensations, however, three subjects experienced a profound perspiration for about ten minutes following the injection of Ro 15-1788.(ABSTRACT TRUNCATED AT 250 WORDS)